IP Library Granted Patent US 11,000,629
Granted Patent B2
US 11,000,629 · App. 16/165,169 · Granted May 11, 2021

Methods related to minimally polarized functional units

Inventor: Denver Lough (Park City, UT)
Assignee: PolarityTE, Inc.
A61L27/3813A01N1/021A01N1/0221A61L27/54C12N5/0625A61L2300/412A61L2430/00C12N2513/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,000,629
App. No.
16/165,169
Granted
May 11, 2021
Kind
B2
Abstract

Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application.

Claims (26)

1. A method, comprising:

a) separating fat and hypodermal elements from dermal and epidermal compartments of a mammalian tissue specimen ex vivo to provide remaining cutaneous elements containing an epidermal compartment, a dermal compartment, and a follicular compartment; and

b) segmenting the epidermal compartment, the dermal compartment, and the follicular compartment to open the follicular compartment and provide a composition, wherein the composition comprises an epidermal segment, a dermal segment, and a segment of the follicular compartment, wherein the segments are interconnected and wherein the segment of the follicular compartment comprises living LGR-expressing stem cells that are exposed,

wherein the composition is capable of regenerating functional tissue comprising epidermis, dermis, and appendages when transplanted to a damaged tissue site in a subject in need thereof.

2. The method of claim 1 , further comprising adding the composition to a pharmaceutically acceptable carrier.

3. The method of claim 2 , wherein the living LGR-expressing stem cells comprise LGR4-expressing stem cells, LGR5-expressing stem cells, LGR6-expressing stem cells, or any combination thereof.

4. The method of claim 2 , further comprising cryopreserving the composition.

5. The method of claim 2 , wherein the mammalian tissue specimen is a human tissue specimen.

6. The method of claim 2 , wherein b) comprises segmenting the epidermal compartment, the dermal compartment, and a bulge of the follicular compartment.

7. The method of claim 2 , wherein b) comprises segmenting the epidermal compartment, the dermal compartment, and a bulb of the follicular compartment.

8. A method comprising applying the composition produced by the method of claim 2 to a select target.

9. The method of claim 8 , wherein the select target is selected from a tissue region, a wound, a void, a defective tissue, or combinations thereof.

10. The method of claim 8 , wherein the select target is an injury involving single or multiple tissue elements.

11. The method of claim 8 , wherein the applying is direct or indirect.

12. The method of claim 11 , wherein the applying is direct and a delivery technique is selected from transplantation, implantation, directed seeding, directed migration, directed tracking, in setting, laminating, injection, or combinations thereof.

13. The method of claim 1 , further comprising adding the composition to a delivery substrate selected from scaffolding, matrix, particle, cells, fiber, or combinations thereof.

14. The method of claim 1 , wherein the living LGR-expressing stem cells comprise LGR4-expressing stem cells, LGR5-expressing stem cells, LGR6-expressing stem cells, or any combination thereof.

15. The method of claim 1 , further comprising cryopreserving the composition.

16. The method of claim 1 , wherein the mammalian tissue specimen is a human tissue specimen.

17. The method of claim 1 , wherein b) comprises segmenting the epidermal compartment, the dermal compartment, and a bulge of the follicular compartment.

18. The method of claim 1 , wherein b) comprises segmenting the epidermal compartment, the dermal compartment, and a bulb of the follicular compartment.

19. A method comprising applying the composition produced by the method of claim 1 to a select target.

20. The method of claim 19 , wherein the select target is selected from a tissue region, a wound, a void, a defective tissue, or combinations thereof.

21. The method of claim 19 , wherein the select target is an injury involving single or multiple tissue elements.

22. The method of claim 19 , wherein the applying is direct or indirect.

23. The method of claim 22 , wherein the applying is direct and a delivery technique is selected from transplantation, implantation, directed seeding, directed migration, directed tracking, in setting, laminating, injection, or combinations thereof.

Assignments (4)
SECURITY INTEREST Recorded May 17, 2024
From: GRANDER ACQUSITION LLC
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
Reel/Frame 067452/0616 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2023
From: POLARITYTE, INC. (PTE); POLARITYTE MD, INC. (PTE MD); POLARITYTE, INC. (PTE NV)
To: GRANDER ACQUISITION LLC
Reel/Frame 064597/0228 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2022
From: LOUGH, DENVER
To: POLARITYTE, INC.
Reel/Frame 061856/0481 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2020
From: LOUGH, DENVER M., DR.
To: POLARITYTE, INC.
Reel/Frame 052837/0682 →
Continuity (3)
Division 14954335 · Nov 30, 2015
Provisional Application 62086526 · Dec 2, 2014
Related Publication 20190046691A1 · Feb 14, 2019